Program Officer · National Academies

Ogan K.
Kumova
PhD

Vaccine Science Immunology Science Policy

Bridging the gap between immunological evidence and national public health decision-making — from the bench to Capitol Hill.

Ogan K. Kumova, PhD
Bench Preclinical vaccine development Candidate design, formulation, and animal models — from basic immunology forward.
Regulatory FDA regulatory science How preclinical evidence is actually weighed for safety and immunogenicity.
Post-Market Post-licensure safety monitoring Federal surveillance systems and the evidence reviews built on them.

About Me

Ogan K. Kumova, PhD
2023 – Present
Program Officer
National Academies of Sciences, Engineering, and Medicine
2020 – 2023
Postdoctoral Fellow
FDA Office of Vaccine Research & Review
2015 – 2020
PhD — Immunology & Microbiology
Drexel University College of Medicine
2013 – 2015
MS — Clinical Infectious Diseases
Drexel University

I’ve been a scientist at heart since I was six — the year I got my first microscope and a subscription to Discovery Kids, which I read cover to cover and then started all over again. I grew up in Turkey as the kid who always asked “why?” No one ever managed to talk me out of it.

My family moved to the United States at the end of middle school, and I finished high school in New Jersey, fitting in every science class the schedule would allow. Around the same time, I began volunteering at the Franklin Institute in Philadelphia. That is where I learned something about myself that took me years to fully act on: I love explaining science as much as I love doing it. Watching the moment a concept clicks for someone — regardless of their age, background, or familiarity with the science — is its own kind of result.

After high school, I knew I wanted to pursue a career in research, so I attended the University of the Sciences in Philadelphia, where I earned dual Bachelor of Science degrees in Biochemistry and Bioinformatics. At the same time, I continued working at the Franklin Institute in roles that ranged from developing workshop curricula and presenting live science shows on the museum floor to directing its overnight camp program. Each role taught me how to meet people where they are and make complicated ideas engaging, understandable, and relevant. What began as a high school volunteer position ultimately grew into a relationship with the Franklin Institute that lasted more than twenty years.

Even before beginning my research career, I was drawn to teaching. I taught at Philadelphia University while continuing to develop science curricula, experiences that reinforced my belief that discovering new knowledge and helping others understand it are equally rewarding.

My research career began at Drexel University College of Medicine, where I worked as a laboratory technician studying Legionella pneumophila — biofilm regulation, OmpA-like proteins, and the molecular machinery the pathogen uses to survive inside human cells. During that time, I realized that I needed to continue my formal education, so I pursued a Master of Science in Clinical Infectious Diseases while continuing my laboratory work.

From there, I met neonatologist Alison J. Carey, MD, and joined her newly established neonatal immunology laboratory as its lab manager. As we worked together, we realized that I had the potential to take on a larger and more independent scientific role. I entered graduate school as her first doctoral student, and a new question took hold of me: Why are newborns so immunologically vulnerable?

That question became the focus of my doctoral research. I studied the developmental differences in antiviral immunity that make newborns particularly susceptible to severe respiratory infections, approaching the problem from multiple angles — from cellular and molecular mechanisms to whole-animal models and translational implications. I earned a competitive fellowship that funded my graduate training, was selected for the 2016 NIH Clinical and Translational Research cohort, and received the Amedeo Bondi Award for Excellence in Research and the Dean’s Excellence Award for Collaborative Research.

Graduate school also strengthened something that has shaped every stage of my career: when I see a need, I step forward and act. I became a strong advocate for graduate students, serving as President of the Biomedical Sciences Graduate Student Association, representing students on the Drexel University Graduate Council, and serving on the College of Medicine’s Biomedical Sciences Executive Committee. I brought student concerns directly into the rooms where decisions were made and worked to ensure that graduate student perspectives informed conversations about curriculum, policy, well-being, and the overall training experience.

I took the same approach to leadership in the laboratory, where I trained and mentored master’s students, neonatology fellows, and junior researchers. I did not simply teach techniques; I helped people learn how to think through scientific questions, troubleshoot problems, communicate their work, and become more confident, independent researchers. For me, leadership has never been about holding a title. It is about recognizing what needs to be done, bringing people together, and taking responsibility for moving the work forward.

I chose my postdoctoral fellowship deliberately. I wanted hands-on translational research and a real understanding of how regulators evaluate scientific evidence, and the FDA’s Office of Vaccines Research and Review offered both. There, as part of an NIH-funded cooperative research center, I developed liposome- and outer membrane vesicle-based vaccine candidates against Neisseria gonorrhoeae. My work extended across the preclinical development process, including antigen selection, protein expression and isolation, vaccine formulation, immunization studies, and the evaluation of systemic and mucosal immune responses.

Just as importantly, I gained firsthand insight into how preclinical evidence is judged — through rigorous study design, GLP standards, regulatory documentation, and the frameworks used to assess vaccine safety and immunogenicity. It changes the way you design an experiment when you understand who will evaluate the data next, what questions they will ask, and what evidence they need to make a decision.

That path eventually led me to the National Academies of Sciences, Engineering, and Medicine, where I work on high-stakes evidence reviews commissioned by federal agencies including the CDC, VA, DoD, and FDA. The work brings together experts from many different fields: epidemiology, immunology, clinical medicine, mechanistic biology, public health, statistics, and policy. Each discipline has its own language, standards of evidence, and way of approaching a question.

My role is often to serve as the bridge among experts from these different disciplines. I translate across fields — not by simplifying away the complexity, but by helping people understand how evidence from one area connects to the questions being asked in another. I help bring mechanistic science into conversation with population-level data, clinical experience into conversation with epidemiology, and scientific findings into a form that can inform policy.

That work requires listening closely, recognizing when experts are talking past one another, and asking the questions that move the discussion forward. It also requires helping people with different types of expertise build a shared understanding of what the evidence shows, where it remains uncertain, and what conclusions it can reasonably support.

It is work that draws on every part of my background: the researcher who wants to understand how something works, the educator who has spent decades teaching science in museums, classrooms, and laboratories, and the leader who is willing to step in, connect people, and turn a complicated problem into a path forward.

Taken together, my career has given me an unusually broad view of how biomedical science moves from discovery to public impact — from basic laboratory research and translational development, through regulatory science at the FDA, to evidence synthesis and national health policy. Along the way, I have worked as a researcher, educator, mentor, and scientific leader, and each role has reinforced the same lesson: the strongest scientific decisions rarely come from one type of evidence or one area of expertise. They come from bringing the right people and perspectives together, asking the right questions, and building meaningful connections among them.

The curiosity that started with a childhood microscope is still the engine. The questions have simply gotten bigger — and so has my appreciation that good science is ultimately about improving people’s lives. I still ask “why?” just as often. The difference now is that the answers can help shape research, policy, and the decisions that affect millions of people.

Research

01
NASEM · Program Officer

Vaccine Safety Evidence Synthesis

Contributes to comprehensive expert consensus studies on vaccine safety commissioned by the CDC, VA, DoD, and FDA — translating complex immunological evidence into actionable national policy recommendations.

+ Expand
02
FDA Office of Vaccine Research · Postdoc

Gonorrhea Vaccine Development

Developed liposome- and outer membrane vesicle-based vaccine candidates against Neisseria gonorrhoeae within the FDA's regulatory science framework, evaluating routes and immunogenicity in murine ascending infection models.

+ Expand
03
Drexel University College of Medicine · PhD

Probiotic Modulation of Neonatal Immunity

Explored whether intranasal Lactobacillus rhamnosus GG administration could rescue neonatal immune defects and restore early viral control during influenza infection — published in PLoS Pathogens.

+ Expand
04
Drexel University College of Medicine · PhD

Developmental Differences in Neonatal CD8+ T Cells

Investigated developmental differences in neonatal CD8+ T cells that limit early viral control — from transcriptional reprogramming to clonal dynamics — across murine and human models.

+ Expand
05
Drexel / Frontiers in Immunology · PhD

T Cell Repertoire in Human Preterm Neonates

Characterized the naïve CD8+ T cell receptor repertoire of extremely preterm neonates, demonstrating convergent recombination and public clonotypes — offering insight into why premature infants face heightened infectious risk.

+ Expand
06
Drexel University · MS

Virulence and Biofilm Formation in Legionella pneumophila

Studied virulence factors and biofilm formation in Legionella pneumophila in the laboratory of Dr. Shira Ninio, characterizing an OmpA-like protein required for efficient intracellular replication.

+ Expand
Research Profiles ResearchGate ORCID

Policy Work

As a Program Officer at the National Academies of Sciences, Engineering, and Medicine, I work within the Biomedical and Health Sciences Program Area (BHS) of the Center for Health, People, and Places (CHPP), where I bring expertise in immunology and vaccine science to support expert consensus studies on vaccine safety, monitoring systems, and military and veteran health — commissioned by the CDC, VA, DoD, and FDA. This work bridges scientific evidence and public health decision-making at the highest levels of government.

Current & Ongoing Projects
VA · DoD

Neurodegenerative Outcomes and Selected Military Exposures

A National Academies committee is conducting a review of existing systematic reviews to gauge the strength of the evidence base linking six categories of military-service exposure — pesticides, jet fuels, solvents, heavy metals, per- and polyfluoroalkyl substances (PFAS), and fine particulate matter (PM2.5) — to eight neurodegenerative conditions. Each exposure type and its subcategories are examined against each outcome. The committee is not performing new systematic reviews or primary analyses of individual-level data; instead it will recommend where future primary studies or systematic reviews are needed.

View Project →
DoD

Direct Neurocognitive Effects of SARS-CoV-2 Infection Across the Lifespan

An ad hoc committee of the National Academies is examining the state of scientific evidence on the direct effects of SARS-CoV-2 infection on neurocognitive function across the lifespan — children, adolescents, working-aged adults, and older adults. The committee will also consider implications for military force readiness, military and veteran health, and health system planning.

View Project →
Published Reports
2025 · CDC

Vaccine Risk Monitoring and Evaluation at the Centers for Disease Control and Prevention

An in-depth evaluation of CDC's vaccine safety monitoring systems and infrastructure, assessing current practices and providing recommendations to strengthen national vaccine risk surveillance.

View Report →
2024 · FDA

Evidence Review of the Adverse Effects of COVID-19 Vaccination and Intramuscular Vaccine Administration

A comprehensive evidence review examining adverse effects associated with COVID-19 vaccines and intramuscular vaccine administration, produced for federal health agencies to inform vaccine safety policy.

View Report →
Congressional Briefings
October 2025

Prepared an invited briefing on Vaccine Risk Monitoring and Evaluation at the Centers for Disease Control and Prevention for Congressional staff of the U.S. House and Senate Appropriations Committees and the Senate HELP Committee.

May 2024

Prepared an invited briefing on COVID-19 vaccine safety for Congressional staff of the U.S. House and Senate Appropriations Committees and the Senate HELP Committee.

Teaching

Teaching has been part of my life since long before I was formally a teacher. It started at the Franklin Institute in Philadelphia, where I walked in as a high school volunteer and ended up staying for more than twenty years. I did nearly every job the floor had: live science shows and demonstrations for the public, workshops built for visiting school groups, and eventually the overnight camp-in program — which I managed and then directed for a season, shepherding several hundred kids and their very tired chaperones through a museum after dark. It was the best informal-education training I could have asked for. You learn quickly how to read a room, how to find the version of an explanation that lands for a six-year-old and the version that lands for their skeptical parent, and that if you can't connect science to something a person already cares about, it doesn't stick. I still teach that way.

I teach science as a process of discovery rather than a collection of facts to memorize. In my classroom, I want students to understand not only what is happening, but why — and how they can work through it themselves. I rely on guided discussion, Socratic questioning, collaborative activities, and real-world case studies. I also deliberately avoid anchoring my courses to a single textbook — drawing instead from primary literature, case studies, and open educational resources. As zero-cost course initiatives like Z-courses and OER adoption become more widespread, I believe removing textbook barriers is one of the most practical ways faculty can support equitable access to education.

My teaching has spanned a wide range of learners — community college students returning to school after years away, undergraduates entering health professions, graduate and medical students, postdoctoral fellows, and neonatology fellows. At Rowan College at Burlington County, I run the Health and Human Microbiology course for health-profession students and also teach Biology I, Biology II, and Basic Microbiology. At Drexel University College of Medicine and Uniformed Services University, I lecture in microbiology, immunology, molecular pathogenesis, and vaccine development.

Good teaching is not about simplifying material until it loses its depth. It's about presenting it with clarity, structure, and relevance — and making sure students feel supported enough to engage actively with challenging ideas.

Teaching & Mentorship

Microbiology, Immunology & Vaccine Development
Drexel University College of Medicine & Uniformed Services University
Health & Human Microbiology · Biology I & II · Basic Microbiology
Rowan College at Burlington County
Instructor & Curriculum Designer
Philadelphia University
Science Educator & Program Developer
The Franklin Institute, Philadelphia
Teaching Assistant
University of the Sciences in Philadelphia
Graduate Student Association President
Drexel University College of Medicine (2 years)

Publications

PubMed — O. Kumova ORCID Profile ResearchGate
2026

Myeloid TLR2 signaling amplifies immunopathology in influenza-infected murine neonates.

Rao AS, Onufer AP, Kumova O, Roberts LTN, Mossabeb R, Pascasio J, Carey AJ. · American Journal of Respiratory Cell and Molecular Biology. 2026 Mar 16:aanag050.

Neonatal ImmunityInfluenzaInnate Immunity
2025

Evaluation of immunization route in induction of vaccine-mediated anti-gonococcal immune responses in a murine model of ascending infection.

Matthias KA, Connolly KL, Jerse AE, Kumova OK, Macintyre AN, Gray MC, Thomas KS, Criss AK, Zielke RA, Li L, Sikora AE, Ramirez-Bencomo F, Thistlethwaite A, Derrick JP, Lu WE, Bash MC. · Journal of Infectious Diseases. 2025;232(5):e765–e777.

VaccinologyGonorrheaMucosal Immunity
2025

Cathelicidin-related antimicrobial peptide (CRAMP) is toxic during neonatal murine influenza virus infection.

Rao AS, Ugwu N, Onufer AP, Kumova O, Carey AJ. · Journal of Immunology. 2025;214(5):1022–1031.

Neonatal ImmunityInfluenzaAntimicrobial Peptides
2025

Vaccine Risk Monitoring and Evaluation at the Centers for Disease Control and Prevention.

Kumova OKContributing Editor · National Academies of Sciences, Engineering, and Medicine. Washington, DC: The National Academies Press. 2025.

Vaccine SafetyCDCScience Policy
2024

Evidence Review of the Adverse Effects of COVID-19 Vaccination and Intramuscular Vaccine Administration.

Kumova OKContributing Editor · National Academies of Sciences, Engineering, and Medicine. Washington, DC: The National Academies Press. 2024.

Vaccine SafetyFDAScience Policy
2022

Severity of neonatal influenza infection is driven by type I interferon and oxidative stress.

Kumova OK, Galani IE, Rao A, Johnson H, Triantafyllia V, Matt SM, Pascasio J, Gaskill PJ, Andreakos E, Katsikis PD, Carey AJ. · Mucosal Immunology. 2022;15(6):1309–1320.

Neonatal ImmunityInfluenzaType I Interferon
2022

Characterization of a novel regulator of biofilm formation in the pathogen Legionella pneumophila.

Marin C, Kumova OK, Ninio S. · Biomolecules. 2022;12(2):225.

Infectious DiseaseLegionellaBiofilm
2021

Chitin-derived AVR-48 prevents experimental bronchopulmonary dysplasia and BPD-associated pulmonary hypertension in newborn mice.

Das P, Acharya S, Prahaladan VM, Kumova OK, Malaeb S, Behera S, Agarwal B, Christensen DJ, Carey AJ, Bhandari V. · International Journal of Molecular Sciences. 2021;22(16):8547.

Pulmonary HealthBronchopulmonary DysplasiaNeonatal Disease
2021

α1,3-Fucosyltransferase-IX, an enzyme of pulmonary endogenous lung stem cell marker SSEA-1, alleviates experimental bronchopulmonary dysplasia.

Chaubey S, Nader YM, Shah D, Kumova OK, Prahaladan V, Carey AJ, Andersson S, Bhandari V. · Pediatric Research. 2021;89(5):1126–1135.

Pulmonary HealthBronchopulmonary DysplasiaStem Cells
2020

Adenosine deaminase-1 enhances germinal center formation and functional antibody responses to HIV-1 envelope DNA and protein vaccines.

Gary E, O'Connor M, Chakhtoura M, Tardif V, Kumova OK, Malherbe DC, Sutton WF, Haigwood NL, Kutzler MA, Haddad EK. · Vaccine. 2020;38(22):3821–3831.

VaccinologyHIVAdjuvants
2019

Lung transcriptional unresponsiveness and loss of early influenza virus control in infected neonates is prevented by intranasal Lactobacillus rhamnosus GG.

Kumova OK, Fike AJ, Thayer JL, Nguyen LT, Mell JC, Pascasio J, Stairiker C, Leon LG, Katsikis PD, Carey AJ. · PLoS Pathogens. 2019;15(10):e1008072.

Neonatal ImmunityInfluenzaProbiotics
2019

Dissecting the defects in the neonatal CD8+ T-cell response.

Fike AJ, Kumova OK, Carey AJ. · Journal of Leukocyte Biology. 2019;106(5):1051–1061.

Neonatal ImmunityCD8+ T CellsAdaptive Immunity
2019

Neonatal influenza-specific effector CTLs retain elevated CD31 levels at the site of infection and have decreased IFN-γ production.

Fike AJ, Kumova OK, Tardif VJ, Carey AJ. · Journal of Leukocyte Biology. 2019;105(3):539–549.

Neonatal ImmunityCD8+ T CellsInfluenza
2017

Public clonotypes and convergent recombination characterize the naïve CD8+ T-cell receptor repertoire of extremely preterm neonates.

Carey AJ, Hope JL, Mueller YM, Fike AJ, Kumova OK, van Zessen DBH, Steegers EAP, van der Burg M, Katsikis PD. · Frontiers in Immunology. 2017;8:1859.

Neonatal ImmunityTCR RepertoirePreterm
2017

Characterization of CD31 expression on murine and human neonatal T lymphocytes during development and activation.

Fike AJ, Nguyen LT, Kumova OK, Carey AJ. · Pediatric Research. 2017;82(1):133–140.

Neonatal ImmunityCD8+ T CellsT Cell Development
2016

A conserved OmpA-like protein in Legionella pneumophila required for efficient intracellular replication.

Goodwin IP, Kumova OK, Ninio S. · FEMS Microbiology Letters. 2016;363(16):fnw173.

Infectious DiseaseLegionellaPathogenesis
2016

Rapid Evolution of the CD8+ TCR Repertoire in Neonatal Mice.

Carey AJ, Gracias DT, Thayer JL, Boesteanu AC, Kumova OK, Mueller YM, Hope JL, Fraietta JA, van Zessen DB, Katsikis PD. · Journal of Immunology. 2016;196(6):2602–2611.

Neonatal ImmunityCD8+ T CellsTCR Repertoire
Documents

Curriculum Vitae

A full academic CV and targeted resumes for academic, government, and industry roles are available below.

Full CVAcademic
Research ResumeBench & Translational Science Policy ResumePolicy & Federal Teaching ResumeEducation Roles

Contact

I'm always happy to connect with colleagues, collaborators, and anyone interested in vaccine science, immunology, or science policy. I welcome conversations about collaboration, shared interests, and new directions.

Thanks for reaching out — I'll be in touch soon.